Fresenius Medical Care (FME) AGM 2025 summary

Opening remarks and agenda

• The meeting was opened by the Chairman, welcoming shareholders, board members, and online participants, with simultaneous translation provided in English and German.

• Organizational details, including voting procedures, attendance, and speaking protocols, were outlined to ensure orderly proceedings.

• The agenda and related documents were made available online and at the venue, with a counter motion to item three noted and published.

Board and executive committee updates

• The full Management and Supervisory Boards were introduced, including new appointments to the Management Board, enhancing expertise and diversity.

• The Supervisory Board expressed confidence in the Management Board's leadership and thanked employees for their dedication.

Financial performance review

• Organic revenue grew by 4% and operating income by 18% in 2024, with a 16% share price increase year-over-year and 44% over two years.

• The FME25 transformation program exceeded targets, raising the savings goal to EUR 750 million by end of 2025.

• Net leverage ratio improved to 2.9x, earning an investment-grade rating from major agencies.

• Divestments of non-core assets and clinics in several regions contributed to a 1.6% revenue headwind but supported strategic focus.